Sohail Saghezchi
Maxillofacial Surgery · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · UCSF Oral and Maxillofacial Surgery · 6 clinicians in this group
Hospitals listed: UCSF Medical Center · Zuckerberg San Francisco General Hosp & Trauma Ctr. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Sohail Saghezchi’s office at (415) 476-9126 to ask if they take your plan before you enroll.
California Medical Board record
Licence A50363 · Current
Licensed to practise in California · since 1992 · expires 2027-10-31 · Temple University School of Medicine.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
- Zuckerberg San Francisco General Hosp & Trauma CtrSan Francisco, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of San Francisco Health Network, which runs 2 hospitalsPatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.449, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.37, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.538, Oct 2024 – Sep 2025
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Zuckerberg San Francisco General Hosp & Trauma Ctr
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.449 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.37 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.538 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0 to 1.91) · 667 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.12 (0.76 to 1.49) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 195.34 (147.34 to 243.34) · 76 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 114 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.2 · 48 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.5 · 201 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.5 · 214 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 261 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 1,351 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.07 to 0.5) · 4,709 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.39 (0.19 to 0.59) · 4,644 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.34 (2.11 to 6.56) · 795 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.59 (0 to 3.28) · 234 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.85 (1.33 to 4.38) · 861 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.95 (0.25 to 17.64) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6 (2.01 to 9.98) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 167 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.79 (0.08 to 1.49) · 4,129 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 35 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.709 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.769 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 41 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 227 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 28.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 75.1 · 239 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.2 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.3 (8.3 to 15.1) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 37 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 132 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.6 (10.4 to 17.9) · 966 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.8 to 1.7) · 88 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,644 patients answered, 16% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$14,403
Medicare paid this office $14,403 for 64 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (45+ min) | 19 | $2,247 | $118 |
| New patient visit (30+ min) | 31 | $1,942 | $63 |
| Short return visit (20+ min) | 13 | $941 | $59 |
Procedures Medicare counted
| Removal of tissue | 1-10 | None |
Who their Medicare patients are
64 Original Medicare patients in 2024. Average age 73 · Women 66% · Also on Medicaid 39% · Health risk score 1.64. Above the middle of the specialty; the typical maxillofacial surgery clinician is at 1.25.
Conditions among them: High blood pressure 56% · Depression 31% · Cancer 19% · Diabetes 17% · Coronary heart disease 17% · Heart failure 17% · COPD 17% · Atrial fibrillation 17%.
The office billed $123,932, Medicare allowed $18,418 and paid $14,403; for 100 services of 19 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 64 | 100 | 73 | 1.64 | $123,932 | $14,403 |
| 2023 | 51 | 81 | 70 | 1.92 | $80,061 | $8,726 |
| 2022 | 41 | 65 | 72 | 1.39 | $30,089 | $7,439 |
| 2021 | 31 | 48 | 72 | 1.29 | $29,167 | $6,437 |
| 2020 | 42 | 70 | 70 | 1.40 | $35,992 | $7,856 |
| 2019 | 54 | 97 | 68 | 1.66 | $80,453 | $15,495 |
| 2018 | 55 | 91 | 68 | 1.78 | $75,879 | $15,383 |
| 2017 | 16 | 21 | 67 | 1.43 | $18,251 | $3,133 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| New patient visit (30+ min) | 31 | $2,038 | $66 |
| Short return visit (20+ min) | 13 | $762 | $59 |
2022: 3 services
| New patient visit (45+ min) | 11 | $1,246 | $113 |
| New patient visit (30+ min) | 16 | $1,033 | $65 |
| Short return visit (20+ min) | 13 | $1,015 | $56 |
2021: 1 service
| New patient visit (30+ min) | 12 | $674 | $56 |
2020: 3 services
| New patient visit (30+ min) | 19 | $1,102 | $58 |
| Short return visit (20+ min) | 11 | $437 | $36 |
| X-ray of lower jaws, upper jaws and teeth | 14 | $136 | $9 |
2019: 2 services
| New patient visit (30+ min) | 29 | $1,361 | $47 |
| Short return visit (20+ min) | 15 | $753 | $38 |
2018: 2 services
| New patient visit (30+ min) | 34 | $1,892 | $56 |
| Short return visit (20+ min) | 15 | $632 | $35 |
2017: 1 service
| New patient visit (30+ min) | 13 | $864 | $66 |
Medicaid work
$18,602 in 2024
Medicaid paid $18,602 for 352 billed services this clinician did in 2024, up to 37 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Service | 175 | $12,171 |
| Service | 135 | $4,020 |
| Service | 42 | $2,411 |
| 2024 | 352 | 3 | 37 | $18,602 |
| 2023 | 548 | 4 | 47 | $33,711 |
| 2022 | 42 | 2 | 15 | $2,208 |
| 2021 | 30 | 1 | 15 | $1,914 |
| 2020 | 113 | 2 | 19 | $5,555 |
| 2019 | 72 | 2 | 29 | $2,937 |
| 2018 | 277 | 2 | 27 | $20,651 |
See the largest Medicaid services in earlier years
2023
| Service | 92 | $10,948 |
| Service | 166 | $10,890 |
| Service | 118 | $6,773 |
| Service | 172 | $5,100 |
2022
| Service | 27 | $1,766 |
| Service | 15 | $443 |
2021
| Service | 30 | $1,914 |
2020
| Service | 62 | $4,092 |
| Service | 51 | $1,463 |
2019
| Service | 50 | $1,485 |
| Service | 22 | $1,452 |
2018
| Service | 198 | $11,250 |
| Service | 79 | $9,401 |
Drugs they prescribed that Part D paid
$1,576
Pharmacies billed $1,576 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 10% of their Part D prescriptions (24 of 245) in 2024. At or below the middle of the specialty; the typical maxillofacial surgery clinician is at 23%.
245 generic and 0 brand-name prescriptions · $1,576 in drug cost · 90 antibiotic prescriptions to 72 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Chlorhexidine Gluconate | 72 | $374 | $5 |
| Amoxicillin | 69 | $262 | $4 |
| Ibuprofen | 44 | $183 | $4 |
| Amoxicillin-Clavulanate Potass | 14 | $100 | $7 |
| Hydrocodone-Acetaminophen | 13 | $85 | $7 |
See all 6 drugs
| Chlorhexidine Gluconate | 72 | $374 | $5 |
| Amoxicillin | 69 | $262 | $4 |
| Ibuprofen | 44 | $183 | $4 |
| Amoxicillin-Clavulanate Potass | 14 | $100 | $7 |
| Hydrocodone-Acetaminophen | 13 | $85 | $7 |
| Oxycodone | 11 | $30 | $3 |
Year by year
| 2024 | 245 | 93 | 10% (24) | 0% | $1,576 |
| 2023 | 217 | 97 | 7% (14) | None | $6,081 |
| 2022 | 164 | 56 | None | None | $1,329 |
| 2021 | 168 | 70 | 8% (14) | None | $1,398 |
| 2020 | 149 | 57 | 11% (17) | 0% | $999 |
| 2019 | 148 | 58 | 15% (22) | None | $1,048 |
| 2018 | 152 | 65 | 20% (30) | 0% | $1,269 |
| 2017 | 55 | 29 | None | 0% | $402 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Amoxicillin | 81 | $336 | $4 |
| Chlorhexidine Gluconate | 51 | $335 | $7 |
| Ibuprofen | 44 | $227 | $5 |
2022: 3 drugs
| Chlorhexidine Gluconate | 60 | $450 | $7 |
| Amoxicillin | 46 | $214 | $5 |
| Ibuprofen | 21 | $114 | $5 |
2021: 4 drugs
| Chlorhexidine Gluconate | 54 | $333 | $6 |
| Amoxicillin | 49 | $177 | $4 |
| Clindamycin | 12 | $93 | $8 |
| Ibuprofen | 17 | $76 | $4 |
2020: 5 drugs
| Clindamycin | 20 | $233 | $12 |
| Chlorhexidine Gluconate | 47 | $222 | $5 |
| Amoxicillin | 37 | $178 | $5 |
| Ibuprofen | 16 | $118 | $7 |
| Hydrocodone-Acetaminophen | 11 | $84 | $8 |
2019: 4 drugs
| Chlorhexidine Gluconate | 56 | $358 | $6 |
| Amoxicillin | 39 | $205 | $5 |
| Hydrocodone-Acetaminophen | 15 | $63 | $4 |
| Ibuprofen | 11 | $51 | $5 |
2018: 4 drugs
| Chlorhexidine Gluconate | 40 | $239 | $6 |
| Hydrocodone-Acetaminophen | 21 | $121 | $6 |
| Ibuprofen | 20 | $108 | $5 |
| Amoxicillin | 24 | $105 | $4 |
2017: 1 drug
| Amoxicillin | 16 | $66 | $4 |
Money from drug and device companies
$8,046 in 2025
| 2025 | 3 | 18 | $6,549 | $8,046 |
| 2024 | 5 | 39 | None | $3,698 |
| 2023 | 6 | 36 | $1,680 | $4,516 |
| 2022 | 5 | 27 | None | $3,344 |
| 2021 | 4 | 22 | None | $1,508 |
| 2020 | 2 | 2 | None | $534 |
| 2019 | 3 | 9 | None | $4,894 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Envista Holdings | Education | $6,549 | 2 payments
|
| DePuy Synthes Sales | Trumatch | $783 | 8 payments
|
| Stryker | Na | $714 | 8 payments
|
See all 18 published payments
| DePuy Synthes Sales | Meals · 2025-12-10 | Trumatch | $129 |
| Stryker | Travel · 2025-10-08 | Na | $253 |
| DePuy Synthes Sales | Meals · 2025-09-24 | Trumatch | $145 |
| Stryker | Meals · 2025-09-20 | None | $39 |
| Stryker | Meals · 2025-09-18 | Vsp System, Vsp Cranial | $157 |
| Stryker | Meals · 2025-09-18 | Na | $22 |
| Stryker | Meals · 2025-09-17 | Vsp System, Vsp Cranial | $14 |
| Stryker | Meals · 2025-09-17 | Patient-Fitted Tmj Reconstructive Prosthesis System | $57 |
| DePuy Synthes Sales | Meals · 2025-08-28 | Matrixorthognathic | $76 |
| DePuy Synthes Sales | Meals · 2025-07-30 | Trumatch | $80 |
| Stryker | Meals · 2025-07-29 | Na | $3 |
| DePuy Synthes Sales | Meals · 2025-07-23 | Matrixorthognathic | $67 |
| DePuy Synthes Sales | Meals · 2025-06-26 | Matrixorthognathic | $109 |
| Stryker | Meals · 2025-06-17 | Patient-Fitted Tmj Reconstructive Prosthesis System | $170 |
| Envista Holdings | Consulting · 2025-04-17 | Education | $4,799 |
| Envista Holdings | Consulting · 2025-04-14 | Education | $1,750 |
| DePuy Synthes Sales | Meals · 2025-03-20 | Matrixmandible | $98 |
| DePuy Synthes Sales | Meals · 2025-01-15 | Trumatch | $79 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,698
| Stryker | Na | $1,916 | 11 payments
|
| DePuy Synthes Sales | Matrixorthognathic | $912 | 13 payments
|
| KLS-Martin L.P. | None | $552 | 8 payments
|
| Medical Device Business Services | None | $240 | 4 payments
|
| Geistlich Pharma North America | Geistlich Bio-Gide | $78 | 3 payments
|
2023: $4,516
| Medical Device Business Services | None | $1,680 | 1 payment
|
| KLS-Martin L.P. | None | $1,535 | 12 payments
|
| DePuy Synthes Sales | Trumatch | $1,047 | 19 payments
|
| Stryker | Vsp System, Vsp Cranial | $201 | 2 payments
|
| Dentsply Sirona | Waveone Gold Conform Fit | $28 | 1 payment
|
| Nobel Biocare USA | Nobelactive | $24 | 1 payment
|
2022: $3,344
| Stryker | Na | $1,649 | 9 payments
|
| DePuy Synthes Sales | Matrixorthognathic | $1,002 | 12 payments
|
| KLS-Martin L.P. | None | $310 | 3 payments
|
| Straumann USA | None | $237 | 2 payments
|
| Checkpoint Surgical | Checkpoint Stimulators | $146 | 1 payment
|
2021: $1,508
| Axogen | Avance Nerve Graft | $1,100 | 6 payments
|
| KLS-Martin L.P. | None | $166 | 1 payment
|
| Zimmer Biomet Holdings | Tmj Replacement System | $136 | 4 payments
|
| Stryker | Na | $107 | 1 payment
|
2020: $534
| KLS-Martin L.P. | None | $517 | 1 payment
|
| Axogen | Avance Nerve Graft | $17 | 1 payment
|
2019: $4,894
| KLS-Martin L.P. | None | $3,898 | 2 payments
|
| Stryker | Vsp Reconstruction | $860 | 4 payments
|
| Axogen | Axoguard Nerve Connector | $135 | 3 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 91.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1588803449
- Licence
- CA 50363California A50363: Current · expires 2027-10-31
- Trained
- University of California, San Francisco School of Medicine, 2015
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 1223G0001X (1223G0001X)
- Mailing address
- 2725 El Camino Real, #109, Santa Clara, CA, 95051
- NPI first listed
- 2009-02-16
- NPI last updated
- 2009-02-16
This is when the NPI record was last certified, not a medical board exam.